Vancouver, British Columbia - TheNewswire – November 23, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CSE:BLR) (Frankfurt:0JJ) (the "Corporation" or "Blackhawk"), is pleased to announce that it has entered into a financing agreement (the "Credit Facility") for up to $10-million. The loan facility was arranged by RiverFort Global Capital Ltd. (a United Kingdom London-based firm regulated by the Financial Conduct Authority) ("RiverFort") and funded by a regulated institutional investor (the "Investor"). The Corporation intends to utilize the proceeds from the Credit Facility to support the Corporation's research undertaken in Trip Pharma as well as for operational and working capital purposes of Blackhawk.
Frederick Pels, Chief Executive Officer of Blackhawk, commented: "this new Credit Facility serves as a proactive step towards continuing to strengthen Blackhawk's balance sheet, improving our long-term financial liquidity and lowering our overall cost of capital. Teaming with RiverFort will allow us to continue growing our investment portfolio while driving returns for our stakeholders with a partner who demonstrates an understanding of the opportunity of lending to venture backed companies."
Pursuant to the terms of the Credit Facility, Blackhawk has agreed to draw down an initial tranche of $2.5-million, with this debt maturing on November 22, 2023, with interest payable by Blackhawk in an amount equal to 10 per cent per annum on the tranche. Any subsequent advances under the loan, will be subject to interest payable at an equivalent rate, to be applied to the term between the date of the relevant advance date and the maturity date. Drawdowns of each subsequent tranche of the Credit Facility will be subject to the satisfaction of customary closing conditions involving Blackhawk and the Investor, including any required regulatory approvals.
The loan provides for 40-per-cent warrant coverage for each advance or drawdown, determined as being 40 per cent of the principal amount of the tranche divided by the Corporation's share price at the time of the advance. The exercise price of the warrants will be set at 140 per cent of the Corporation's share price at the time of the advance and the warrants will expire three years after the date they are granted. In connection with the initial tranche, Blackhawk has issued 1,538,461 warrants to the Investor whereby each warrant will entitle the Investor to purchase one common share of the Corporation at a price of $0.91 per share until November 22, 2024.
As part of the Credit Facility, the Investor will have the option to convert up to 100 per cent of the principal amount of the loan into shares at a fixed conversion price equal to 120 per cent of the market price of the shares at the time of the applicable drawdown. The fixed conversion price for the initial tranche is $0.78 per share. In addition, the Investor may at its option, once every 30 days, request and require that the debt represented by the interest that has been deemed to accrue on the loan be converted into shares at a price equal to 90 per cent of the last closing price of the shares on the day prior to the notice of such conversion.
Gytis Martinkus, chief executive officer of RiverFort, stated:
"The team here at RiverFort has been very impressed with the work being undertaken for Trip Pharma and the operations of LeichtMind Clinics, as well as the professionalism of the Blackhawk group as a whole. The research in the microdosing is market-leading and the team at Blackhawk have demonstrated its advanced applications to us in detail. We look forward to seeing the news regarding the progression of this research and development with its associated clinical trials."
Blackhawk, the Investor and RiverFort are independent and operate at arm's length from one another. The loan agreement and any warrants issued to the Investor pursuant to the loan agreement will be issued pursuant to prospectus exemptions set out in National Instrument 45-106 – Prospectus Exemptions and any shares issued upon conversion of the loan or upon exercise of the warrants will, if issued, also be issued pursuant to prospectus exemptions set out in NI 45-106 and will be subject to applicable statutory hold periods under National Instrument 45-102 – Resale of Securities.
About Blackhawk Growth
Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.
The Corporation diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please join the conversation on our Blackhawk group supporter's telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.
For further information please contact:
Frederick Pels, Chief Executive Officer
(403)-991-7737
fred@blackhawkgrowth.com
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Corporation within the meaning of applicable securities laws, including with respect to use of the proceeds from the Credit Facility. The Corporation provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Corporation 's public filings under the Corporation's SEDAR profile at www.sedar.com. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
Copyright (c) 2021 TheNewswire - All rights reserved.
温哥華,不列顛哥倫比亞省-The Newswire(新聞通訊社)-2021年11月23日-黑鷹增長公司(CSE:BLR)(CSE:BLR)(法蘭克福:0JJ)(“公司“或”黑鷹),很高興地宣佈,它已達成一項融資協議(信貸安排“)最多1000萬美元。這筆貸款由RiverFort Global Capital Ltd.(一家總部位於倫敦、受金融市場行為監管局監管的英國公司)安排。”河堡“),並由受監管的機構投資者(”投資者“)。本公司擬利用信貸融資所得款項,支持本公司在TRIP Pharma進行的研究,以及用作黑鷹的營運和營運資本用途。
BlackHawk首席執行官弗雷德裏克·佩爾斯(Frederick Pels)評論説:“這一新的信貸安排是朝着繼續加強BlackHawk資產負債表邁出的積極一步,改善了我們的長期財務流動性,降低了我們的整體資金成本。與RiverFort的合作將使我們能夠繼續擴大我們的投資組合,同時與一個能夠證明理解向風險投資支持的公司提供貸款機會的合作伙伴一起為我們的利益相關者帶來回報。”
根據信貸安排的條款,黑鷹已同意提取首批250萬美元,這筆債務將於2023年11月22日到期,黑鷹應支付的利息相當於該部分的年息10%。貸款項下的任何後續墊款將按等值利率支付利息,適用於相關墊款日期和到期日之間的期限。信貸安排後續各期的提款將取決於涉及BlackHawk和投資者的慣例成交條件(包括任何必要的監管批准)的滿足情況。
這筆貸款為每筆墊款或提款提供40%的認股權證擔保,確定為該部分本金金額的40%除以公司在墊款時的股價。認股權證的行使價將定為該公司預支時股價的百分之一百四十,而認股權證將在批出日期後三年屆滿。關於第一批,黑鷹公司已向投資者發行了1,538,461份認股權證,據此每份認股權證將使投資者有權在2024年11月22日之前以每股0.91美元的價格購買公司的一股普通股。
作為信貸安排的一部分,投資者將有權以相當於適用提款時股票市價120%的固定轉換價格,將最高100%的貸款本金轉換為股票。首批股票的固定轉換價格為每股0.78美元。此外,投資者可以每30天一次的選擇權,請求並要求將已被視為貸款應計利息所代表的債務轉換為股票,轉換價格相當於轉換通知前一天股票最後收盤價的90%。
RiverFort首席執行官吉蒂斯·馬丁庫斯(Gytis Martinkus)表示:
RiverFort的團隊對Trip Pharma和LeichtMind診所正在進行的工作以及黑鷹集團作為一個整體的專業精神印象非常深刻。在微劑量方面的研究處於市場領先地位,BlackHawk的團隊已經向我們詳細展示了它的先進應用。我們期待着看到有關這一研究和開發及其相關臨牀試驗進展的消息。“
黑鷹、The Investor和RiverFort是獨立的,彼此之間保持一定的距離。貸款協議及根據貸款協議向投資者發行的任何認股權證,將根據National Instrument 45-106所載的招股章程豁免條款發行-招股章程的豁免而在轉換貸款或行使認股權證時發行的任何股份,如已發行,亦將依據NI 45-106列明的招股章程豁免而發行,並將受國家文書45-102所指的適用法定持有期所規限-證券轉售.
關於黑鷹成長
黑鷹是一家投資控股公司,希望通過收購和發展高增長公司為其股東創造實質性價值。該公司將投資重點放在加拿大和美國的健康、大麻和大麻二醇行業。它的公司組合包括SAC製藥公司、LeichtMind診所、Noble Hemp公司、Spaced Food公司、NuWave食品公司和MindBio治療公司。黑鷹繼續將其投資轉化為現金流,並正在以超乎尋常的速度增長。
該公司勤奮地通過公司官方Youtube頻道https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A的視頻發佈最新消息
請在https://t.me/Blackhawkgrowthcorp上加入我們的黑鷹團體支持者電報羣的對話並在線訪問我們的網站Https://www.blackhawkgrowth.com.
如需更多信息,請聯繫:
首席執行官弗雷德裏克·佩爾斯(Frederick Pels)
(403)-991-7737
弗雷德@Blackhawkgrowth.com
關於前瞻性陳述的注意事項
本新聞稿中的所有聲明,除對歷史事實的陳述,是適用證券法所指的有關本公司的“前瞻性信息”,包括有關使用來自信貸安排的收益。該公司提供前瞻性陳述的目的是傳達有關當前對未來的期望和計劃的信息,請讀者注意,此類陳述可能不適合用於其他目的。就其性質而言,這些信息受固有風險和不確定性的影響,這些風險和不確定性可能是一般性或具體性的,並可能導致預期、預測或結論被證明不準確,假設可能不正確,目標、戰略目標和優先事項無法實現。這些風險和不確定性包括但不限於該公司在www.sedar.com的SEDAR檔案中公開提交的文件中確定和報告的風險和不確定性。儘管公司試圖找出可能導致實際行動、事件或結果與前瞻性信息中描述的大不相同的重要因素,但也可能有其他因素導致行動、事件或結果與預期、估計或預期的不同。不能保證這些信息將被證明是準確的,因為實際結果和未來事件可能與此類聲明中預期的大不相同。除非法律要求,否則公司不會因為新信息、未來事件或其他原因而更新或修改任何前瞻性信息,也不承擔任何義務。
版權所有(C)2021 TheNewswire-保留所有權利。